Objective: Circulating cardiac troponin has been associated with adverse prognosis in the acute respiratory distress syndrome in small and single-center studies; however, comprehensive studies of myocardial injury in acute respiratory distress syndrome using modern high-sensitivity troponin assays, which can detect troponin at much lower circulating concentrations, have not been performed. Design: We performed a prospective cohort study. Setting: We included patients enrolled in previously completed trials of acute respiratory distress syndrome. Patients: One thousand fifty-seven acute respiratory distress syndrome patients were included. Interventions: To determine the association of circulating high-sensitivity troponin I (Abbott ARCHITECT), with acute respiratory distress syndrome outcomes, we measured high-sensitivity troponin I within 24 hours of intubation. The primary outcome was 60-day mortality. Measurements and Main Results: Detectable high-sensitivity troponin I was present in 94% of patients; 38% of patients had detectable levels below the 99th percentile of a healthy reference population (26 ng/L), whereas 56% of patients had levels above the 99th percentile cut point. After multivariable adjustment, age, cause of acute respiratory distress syndrome, temperature, heart rate, vasopressor use, Sequential Organ Failure Assessment score, creatinine, and Pco 2 were associated with higher high-sensitivity troponin I concentration. After adjustment for age, sex, and randomized trial assignment, the hazard ratio for 60-day mortality comparing the fifth to the first quintiles of high-sensitivity troponin I was 1.61 (95% CI, 1.11-2.32; p trend = 0.003). Adjusting for Sequential Organ Failure Assessment score suggested that this association was not independent of disease severity (hazard ratio, 0.95; 95% CI, 0.64-1.39; p = 0.93). Conclusions: Circulating troponin is detectable in over 90% of patients with acute respiratory distress syndrome and is associated with degree of critical illness. The magnitude of myocardial injury correlated with mortality. (Crit Care Med 2017; 45:1709-1717 
Cardiac involvement, manifested by hemodynamic (3) and echocardiographic (4) evidence of right heart dysfunction, has emerged as an important predictor of outcome in ARDS, which may be amenable to targeted therapy (5) . High-sensitivity assays for cardiac troponin (hsTn) detect myocardial injury with very high analytical sensitivity (6) , and myocardial injury even at these low levels has prognostic significance (7) . Although elevated troponin levels have been associated with adverse prognosis in ARDS, the evidence is limited to small or single-center studies using conventional rather than hsTn assays (8, 9) . The prognostic relevance of very low concentrations of circulating troponin assessed by hsTn assays in ARDS has not been established (7, 10, 11) ; however, use of these assays could identify many more ARDS patients manifesting myocardial injury and facilitate investigation into mechanism of myocardial injury in ARDS. Consequently, we performed a multicenter cohort study to determine the association of hsTn with mortality, ICU-free days, and ventilator-free days in ARDS. We hypothesized that higher hsTn values would be associated with worse ARDS outcomes. We also investigated which clinical factors, such as comorbidities and treatments, were associated with hsTn concentration in ARDS.
METHODS

Patient Population
Our study population included patients from two National Heart, Lung, and Blood Institute-sponsored ARDS Network trials, the Assessment of Low tidal Volume and elevated End-expiratory volume to Obviate Lung Injury (ALVEOLI) trial (12) of higher versus lower positive end-expiratory pressure (PEEP) and the Fluid and Catheter Treatment Trial (FACTT) (13, 14) of fluid management and hemodynamic monitoring strategies. The inclusion criteria and ARDS definition for both trials were identical and included a ratio of partial pressure of oxygen (Pao 2 ) to fraction of inspired oxygen (Fio 2 ) less than 300, bilateral pulmonary infiltrates, and no clinical evidence of left atrial hypertension. Both trials excluded patients with acute myocardial infarction and those patients with severe chronic pulmonary or neuromuscular disease. There were very few patients with chronic heart failure enrolled in FACTT-27 of 1,000 patients were noted to have a history of prior heart failure. The ALVEOLI trial dataset did not report information regarding prior episodes of heart failure. Patients on hemodialysis were excluded from the FACTT trial, and no comment is made regarding hemodialysis status in the ALVEOLI trial dataset. The ALVEOLI trial, conducted in 23 ICUs, randomized 549 subjects with ARDS already receiving low tidal volume ventilation to receive treatment with a lower or a higher PEEP strategy. FACTT randomized 1,000 subjects with ARDS from 20 ICUs in a 2 × 2 design to a liberal or conservative fluid management strategy and to fluid management strategies guided by a pulmonary artery catheter or central venous catheter placement (13, 14) .
We obtained plasma samples via the National Institutes of Health Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC) (15) . Samples were drawn within the first 24 hours of study randomization (day 0). Our study cohort consisted of all patients in both trials who had plasma for analysis and who were intubated within the 24 hours prior to trial enrollment. We excluded patients intubated 24 hours or more before trial enrollment and one patient from the ALVEOLI trial with missing outcome information (Supplemental Fig. 1 , Supplemental Digital Content 1, http:// links.lww.com/CCM/C791). The final sample size was 1,057 participants (417 from ALVEOLI and 640 from FACTT).
The FACTT and ALVEOLI studies were approved by all participating institutional review boards (12) (13) (14) . The Johns Hopkins Hospital Institutional Review Board exempted our study, given that all study data were publicly available from the BIOLINCC program (15) and that the datasets contained no protected health information.
hsTnI Measurements
We measured cardiac troponin at Johns Hopkins Hospital in EDTA-anticoagulated plasma using the ARCHITECT STAT hsTnI assay (Abbott Laboratories, Chicago, IL). The applied limit of detection (LoD) was 2 ng/L. For subjects with undetectable levels (hsTnI < LoD; n = 64), the value was set at 1.3 ng/L for analysis. The upper reference limit (URL), corresponding to the 99th percentile value of a healthy reference population, was 26 ng/L (11, 16) . The number of patients with troponin levels greater than 99th percentile reference using sex-specific cutpoints of 16 ng/L for women and 34 ng/L (17) is also reported.
Study Outcomes and Covariates
Our primary outcome was in hospital death prior to 60 days. Secondary outcomes included ventilator-free days, defined as the number of days within 30 days of trial enrollment that the patient was not receiving mechanical ventilation, and ICU-free days, defined as the number of days within the first 30 days of trial enrollment that the patient was not in the ICU. The methods for covariate assessment including demographic and clinical and laboratory data have been described in detail elsewhere (12) (13) (14) . The Sequential Organ Failure Assessment (SOFA) score was calculated as a marker of global illness severity (18) and the Murray Lung Injury Score as a marker of ARDS severity (19) .
Statistical Analysis
Although information for the main exposure variable-hsTnI levels-and for all study outcomes was complete, information on some covariates was missing in some participants (Supplemental Table 1 , Supplemental Digital Content 1, http://links.lww. com/CCM/C791). We thus used multiple imputation to obtain unbiased estimates of the association between hsTnI and study outcomes taking into account missing data. Multiple imputation was performed using chained equations with 50 imputed datasets. The results with and without multiple imputation were similar. All results in the article used multiple imputation methods.
For the main analysis, hsTnI was categorized in quintiles based on the overall sample distribution. We estimated hazard ratios (HR) with 95% CIs for 60-day mortality (primary outcome) comparing the four highest quintiles of hsTnI to the lowest quintile using Cox proportional hazards models. The proportional hazards assumption was met in all cases. For the secondary outcomes, we estimated average differences with 95% CI in ventilator-free days and ICU-free days comparing the four highest quintiles of hsTnI to the lowest quintile using multiple linear regression. For analyses of the primary and secondary outcomes, we used three models with progressive degrees of adjustment. Model 1 included age, sex, and randomized trial assignment. Model 2 further adjusted for SOFA score. Model 3 further adjusted for use of vasopressors and heart rate.
As secondary analyses, we used hsTnI as a log e -transformed continuous variable and calculated the HR for mortality and the average difference in ventilator-free days and ICU-free days comparing participants at the 90th versus the 10th percentiles of the hsTnI distribution (804.7 and 2.8 ng/L, respectively). For sensitivity analyses, we also grouped hsTnI into assay-defined clinical categories as less than 2 ng/L (undetectable), 2 to less than 26 ng/L (hsTn present but less than 99% reference value), 26 to less than 130 ng/L ("positive" hsTn), and greater than or equal to 130 ng/L (>5 times the 99% cutpoint), and the findings were similar to the quintile-based analysis (not shown).
To evaluate determinants of hsTnI at day 0, we used multiple linear regression with log e -transformed hsTnI as dependent variable. The final model included variables with p less than 0.10 in univariate analyses. Nonlinear associations were evaluated using restricted cubic splines with three knots at the fifth, 50th, and 95th percentiles of the predictor variables.
A two-tailed p value less than 0.05 was considered statistically significant. Statistical analyses were performed using Stata version 14.0 (StataCorp, College Station, TX).
RESULTS
Clinical Correlates of hsTn hsTnI was detected in 94% of the cohort (Fig. 1) ; 38% of the cohort had detectable hsTnI levels but below the 99th percentile of a healthy reference population, whereas 56% of patients had levels above the 99th percentile URL. Using sex-specific cutoffs, 59.4% of the cohort had levels above the 99th percentile cutpoint. ARDS patients with higher hsTnI levels were older, had higher average heart rate, temperature, tidal volume, serum creatinine, and SOFA scores, and were more likely to be non-White and have been treated with vasopressors. The primary cause of ARDS was more likely to be sepsis, transfusion, or trauma than aspiration or pneumonia ( Table 1) . Lower pH and lower Pco 2 were also associated with higher hsTnI levels. Serum creatinine concentration, heart rate, and SOFA score had the strongest univariate associations with higher hsTnI levels ( Table 2 ). In contrast, mean arterial pressure and ventilator variables such as PEEP, plateau pressure, and tidal volume were not associated with hsTnI levels after adjustment. After multivariable adjustment, age, cause of ARDS, temperature, heart rate, vasopressor use, SOFA score, creatinine, and Pco 2 remained associated with higher hsTnI concentration.
hsTnI and Mortality in ARDS
After 60 days, cumulative mortality in quintiles 1-5 of hsTnI at day 0 was 22.2, 26.1, 26.4, 28.4, and 34.9%, respectively (p = 0.02) (Fig. 2) . After adjustment for age, sex, and randomized trial assignment, the HR for 60-day mortality comparing the fifth to the first quintiles of hsTnI was 1.61 (95% CI, 1.11-2.32; p trend = 0.003) ( Table 3) . This association, however, was not independent of the severity of underlying illness assessed by SOFA score, heart rate, and vasopressor requirement. Increasing hsTnI concentration was associated with fewer ventilator-free days and ICUfree days in a model adjusted for age, sex, and randomized trial assignment (Supplemental 
DISCUSSION
We present the largest multicenter cohort study assessing the prevalence and prognostic impact of circulating troponin in ARDS. We report three major findings. First, circulating hsTnI levels can be detected in almost all patients with ARDS (94% of our study population), and 56% of the population had hsTnI levels greater than 99th percentile of a healthy reference population, suggesting that myocardial injury is highly prevalent in ARDS. Second, elevated hsTnI levels were associated with higher mortality and lower ventilator-free and ICU-free days, indicating worse clinical prognosis. Third, indicators of the severity of underlining critical illness, such as SOFA score, heart rate, and vasopressor use, were associated with higher hsTnI levels. After adjusting for these clinical factors, hsTn was not independently associated with outcomes in ARDS beyond these potential mechanisms of myocardial injury. Our findings provide strong evidence that myocardial damage is common in ARDS and is associated with outcome as a function of underlying critical illness.
Prevalence of Myocardial Injury
With an hsTn assay, we could identify some level of myocardial injury in over 90% of ARDS patients and hsTnI levels above the 99th percentile of a healthy reference population in 56% of participants. In two smaller single-center studies of 177 and 305 ARDS patients using conventional (non-high sensitivity) troponin assays, 67% of patients had detectable troponin levels (9) and 55% had levels greater than 99% cutpoint of the conventional assay (8) . Overall mortality in both these studies was greater than 40%, higher than our reported overall mortality of 22%. This may reflect a discrepancy between the illness of patients enrolled in clinical trials versus those seen in clinical practice. Using a high-sensitivity assay thus seems to result in a substantial increase in the number of ARDS patients identified with myonecrosis. Using an hsTn assay, 85% of 995 patients with sepsis (of whom 70% received mechanical ventilation) had detectable troponin levels (20) , which is consistent with our findings. As hsTn assays continue to gain widespread use in regions around the world, clinicians should be mindful that these assays will detect circulating troponin in nearly all patients with ARDS.
Causes of Elevated Troponin
Circulating troponin is associated with several syndromes including acute myocardial infarction due to intracoronary thrombus (type I myocardial infarction), oxygen supplydemand mismatch at the cardiac myocyte level with signs and symptoms of cardiac ischemia (type II myocardial infarction), and acute or chronic myocardial injury not meeting criteria for myocardial infarction (21) . In the FACTT and ALVEOLI trials, patients were excluded if they had signs or symptoms of acute cardiac ischemia (12-14) ; thus, most of the myocardial injury in our cohort most likely represents acute myocardial injury without infarction. Myocardial infarction was not an adjudicated endpoint in either trial. Indeed, increased serum troponin concentrations have been observed after rapid atrial pacing without infarction (22, 23) , in the pro-inflammatory milieu of sepsis (20) and after increased cardiac work in stress testing (24) . Potential mechanisms for circulating troponin levels in ARDS patients include myocyte necrosis in the setting of critical illness (25) , as well as cellular changes without myocyte necrosis (26) including increased myocyte permeability, membrane blebs, or cell release of troponin degradation products (22) .
Factors associated with increased troponin in our study included markers of other organ dysfunction such as creatinine and SOFA score, indices of ventilation such as pH and Pco 2 , as well as heart rate and body temperature. Elevated troponin in ARDS was also associated with more tricuspid regurgitation and regional wall motion abnormalities on echocardiography (9) in other studies. Given that hemodynamic and echocardiographic right ventricular function is associated with outcome in ARDS (3, 4, 27) , the cause-effect relationship between myocardial injury and right ventricular function in ARDS should be further studied.
Troponin and Outcomes
In our study, circulating hsTnI levels were associated with ARDS outcome in minimally adjusted models and the association was no longer present after adjusting for underlying critical illness. This contrasts with a prior prospective single-center study of 177 ARDS patients in which troponin was independently associated with mortality adjusting for Acute Physiology and Chronic Health Evaluation (APACHE) score (9) . In another small singlecenter study, troponin levels were independently associated with mortality in ARDS, but the association was not present among subgroups of patients with higher APACHE scores and among those with higher age (8) . Several factors could account for the observed differences between our results and studies reporting an independent association of troponin level with ARDS outcomes, including single-center versus multi-center study design, different enrollment criteria or patient profile in ARDS Network studies (12) (13) (14) compared with ARDS patients in clinical practice (1) , and possible selection bias in prior trials. Finally, our results in ARDS were similar to a study of elevated troponin levels in patients with severe sepsis (20) , in which troponin levels were no longer predictive of outcomes after adjustment for measures of illness severity. It is possible that troponin elevation manifests as a result of critical illness through several potential mechanisms. Whether targeting treatment to reduce troponin elevation could improve clinical outcomes requires further study.
Therapeutic Implications
Whether treatment aimed at reducing myocardial injury would improve outcomes is not known. Esmolol to control heart rate in sepsis was associated with reduced mortality (28) , but it is unclear if this effect was mediated through reduced myocardial injury. Propranolol in severely burned children reduced heart rate and improved catabolism (29) . In animal models, β-agonism was associated with increased lipopolysaccharideinduced myocyte necrosis (30) and β-blockade improved cardiac function (28) , but the clinical implications of these experimental findings are unclear. Treatments targeted at alleviating right ventricular afterload and reducing right ventricular strain in ARDS are also appealing (27) . Limitations of our study include observational design, although the parent trials and endpoints were determined prospectively. Not every enrolled patient in FACTT and ALVEOLI had available plasma at the time of intubation. Furthermore, there was no information on electrocardiography or assessment of cardiac structure or function, and the association of these factors with troponin in ARDS would shed important light on the mechanism of injury including possible occult myocardial infarction. Serial measurements of troponin within the first 24 hours were not available, and such measurements could provide clarity on the mechanism of myocardial injury. Data on concomitant medical therapy such as with beta blockers, aspirin, and anticoagulants were not available for our cohort. Finally, the mechanism of death in ARDS was unavailable, and it is still possible that troponin levels could be predictive of deaths with a major cardiovascular component. The mode of death among ARDS patients with increased troponin levels should be assessed in future studies.
In conclusion, circulating cardiac troponin detected by a high-sensitivity assay is present in over 90% of patients. Elevated hsTnI was associated with markers of severity of critical illness and did not confer incremental information regarding survival, ventilator-free days or ICU-free days. Thus, the extent of myocardial injury correlates with underlying critical illness in ARDS and is another indicator of end-organ dysfunction in this syndrome. Future studies should further assess the mechanisms of myocardial injury in ARDS, which could identify pathophysiologic targets to improve outcomes.
